SCHEMBL6387

SCHEMBL6387

N#Cc1ccc([N+](=O)[O-])c(Cl)c1

nearest known ligand 0.74

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
VCAM1 P19320 5/20 0.74
MAPK1 P28482 2/20 0.58
TSHR P16473 1/20 0.58
MERTK Q12866 2/20 0.57
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
MMP1 P03956 1/20 0.46
MMP2 P08253 1/20 0.46
MMP9 P14780 1/20 0.46
MMP8 P22894 1/20 0.46
MMP13 P45452 1/20 0.46
MAPT P10636 3/20 0.46
TDP1 Q9NUW8 2/20 0.46
PDE7A Q13946 1/20 0.45
KAT2B Q92831 1/20 0.44
F2 P00734 1/20 0.43
PRSS1 P07477 1/20 0.43
PRSS2 P07478 1/20 0.43
PRSS3 P35030 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6463 0.85 VCAM1 (1.00) VCAM1MAPK1MERTKMAPTTDP1
SCHEMBL12253372 0.85 VCAM1 (1.00) VCAM1MAPK1MERTKMAPTTDP1
SCHEMBL10348032 0.83 TSHR (0.60) VCAM1MAPK1TSHRMERTKCA1
SCHEMBL4477143 0.82 VCAM1 (0.70) VCAM1MAPK1TSHRMERTKMAPT
SCHEMBL16954831 0.81 TSHR (0.58) VCAM1MAPK1TSHRMERTKCA1
SCHEMBL4385438 0.79 VCAM1 (0.61) VCAM1MAPK1MERTKMAPTTDP1
SCHEMBL16792385 0.79 MERTK (0.55) VCAM1MAPK1TSHRMERTKMAPT
SCHEMBL16387399 0.79 VCAM1 (0.66) VCAM1MAPK1TSHRMERTKMAPT
SCHEMBL14220808 0.78 VCAM1 (0.59) VCAM1MAPK1MERTKMAPTTDP1
SCHEMBL1511983 0.78 VCAM1 (0.59) VCAM1MAPK1MERTKMAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122080074-A Tetradentate ring metal platinum (II) complex and organic electroluminescent device comprising same 2026-05-26 CN disclosed
CN-118666780-A Method for preparing morpholinosulfonamide compound by microwave promotion 邵阳学院 2024-09-20 CN disclosed
CN-116120190-B Method for preparing o-nitroaniline compound and application of o-nitroaniline compound 邵阳学院 2024-08-23 CN disclosed
CN-116120190-A Method for preparing o-nitroaniline compound and application of o-nitroaniline compound 邵阳学院 2023-05-16 CN disclosed
EP-3490552-B1 SELECTIVE BROMODOMAIN INHIBITION OF FUNGAL BDF1 UNIV SOUTHERN CALIFORNIA (US) 2022-11-23 EP disclosed
US-10918647-B2 Selective bromodomain inhibition of fungal Bdf1 UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2021-02-16 US disclosed
US-20190240232-A1 SELECTIVE BROMODOMAIN INHIBITION OF FUNGAL BDF1 UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2019-08-08 US disclosed
EP-3490552-A1 SELECTIVE BROMODOMAIN INHIBITION OF FUNGAL BDF1 University of Southern California (US) 2019-06-05 EP disclosed
WO-2018022802-A1 SELECTIVE BROMODOMAIN INHIBITION OF FUNGAL BDF1 UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2018-02-01 WO disclosed
EP-2493310-A1 BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS GlaxoSmithKline LLC (US) 2012-09-05 EP disclosed
WO-2002032422-A2 EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS PFIZER PHARMACEUTICALS INC. (JP) 2002-04-25 WO disclosed
EP-0292979-B1 NEW ALKANESULFONANILIDE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-07-21 EP disclosed
CN-1019388-B Process for preparing N-alkylsulfonamide derivatives FUJISAWA PHARMACEUTICAL CO (JP) 1992-12-09 CN disclosed
EP-0273369-B1 NEW ALKANESULFONANILIDE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-03-04 EP disclosed
US-5034417-A Antiinflammatory agents or analgesics FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-07-23 US disclosed
US-4866091-A ANTINFLAMMATORY AGENTS, ANALGESICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-09-12 US disclosed
CN-88103277-A Novel N-alkane sulfonyl aniline derivatives and preparation method thereof and the pharmaceutical composition that comprises this material 1988-12-07 CN disclosed
EP-0292979-A2 New alkanesulfonanilide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1988-11-30 EP disclosed
CN-87108295-A New alkane sulfonyl aniline derivative and its medicinal compositions and preparation method 1988-07-13 CN disclosed
EP-0273369-A2 New alkanesulfonanilide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1988-07-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10918647-B2 Selective bromodomain inhibition of fungal Bdf1 BRPF3, BRD3, BRD1 VCAM1 4067/4885MAPK1 945/4885TSHR 4529/4885
US-20190240232-A1 SELECTIVE BROMODOMAIN INHIBITION OF FUNGAL BDF1 BRPF3, BRD3, BRD1 VCAM1 4067/4885MAPK1 945/4885TSHR 4529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.